

This is a copy of a chat between Claude and Lars S. Content may include unverified or unsafe content that do not represent the views of Anthropic. Shared snapshot may contain attachments and data not displayed here. [Report](#)

LS Which FDA-approved drugs target the gene KIT in DGIdb?

L `get_drug_interactions_for_gene_list`


Based on DGIdb, here are the **FDA-approved drugs that target the KIT gene**, ranked by interaction score:

Drug	Interaction Type	Interaction Score
Avapritinib	Inhibitor (Inhibitory)	2.09
Ripretinib	Inhibitor (Inhibitory)	1.60
Imatinib	Inhibitor (Inhibitory)	1.05
Nilotinib	Inhibitor (Inhibitory)	0.65
Quizartinib	Inhibitor (Inhibitory)	0.61
Sunitinib	Inhibitor (Inhibitory)	0.50
Regorafenib	Inhibitor (Inhibitory)	0.35
Ponatinib	—	0.33
Toripalimab	—	0.31
Dasatinib	Inhibitor (Inhibitory)	0.29
Pexidartinib	Inhibitor (Inhibitory)	0.26
Midostaurin	Inhibitor (Inhibitory)	0.21
Masitinib	Inhibitor (Inhibitory)	0.18

Key observations:

- Most KIT-targeting drugs are **tyrosine kinase inhibitors** with inhibitory activity
- **Avapritinib** and **Ripretinib** have the highest interaction scores—these are newer agents specifically developed for KIT-mutant gastrointestinal stromal tumors (GIST)
- **Imatinib** is the classic first-line KIT inhibitor, with extensive supporting evidence from multiple databases including [CIViC](#), [OncoKB](#), and [PharmGKB](#)

Data sources include CIViC, OncoKB, ChEMBL, PharmGKB, TTD, and others.

 Turn on web search in Search and tools menu. Otherwise, links provided may not be accurate or up to date.

Start your own conversation

